Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients

Inclusion Criteria: * Cardiovascular disease (including history of stroke or transient ischaemic attack) * Documented evidence of resistance to aspirin * Capable of comprehending and communicating effectively with the investigator and staff and of providing informed consent. * Willing to give informed consent prior to participation in the trial. Exclusion Criteria: * Any clinically significant condition other than cardiovascular disease. * Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings. * Use of dipyridamole, clopidogrel, ticlopidine or any non-steroidal anti-inflammatory agent (NSAID)(including COX-2 inhibitors) during the two weeks before randomisation and during the trial. * Active peptic ulceration or history of peptic ulcer disease. * Known history of or suspected hypersensitivity to dipyridamole, aspirin, any NSAID or any other component of the test drugs. * History of any bleeding disorder. * History of cerebral haemorrhage. * Resting seated blood pressure less than 90/60mmHg. * Participation in any drug clinical trial within sixteen weeks prior to the start of the trial. * Any indication of current or previous abuse of alcohol, solvents or drugs. * Asthma. * Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (e.g. oral contraceptives, intrauterine devices or surgically sterile). * Previous participation in the randomisation phase of this clinical trial.